SOURCE OF FUNDING AND OUTCOME OF CLINICAL-TRIALS
SOURCE OF FUNDING AND OUTCOME OF CLINICAL-TRIALS
复制标题
DOI：
10.1007/bf02602327
复制
发表时间：
1986-05-01
影响因子：
5.7
通讯作者：
DAVIDSON, RA
中科院分区：
文献类型：
--
作者：
DAVIDSON, RA
由于最近对利益冲突的担忧和已发表的研究，作者分析了107项对照临床试验。研究被归类为支持新疗法或传统疗法，并得到制药制造商的支持或普遍支持。71%的试验支持新疗法；其中43%是由制药公司资助的。在31项支持传统疗法的试验中，只有4项(13%)得到了制药公司的支持。资金来源和研究结果之间有统计学上的显著关联(p=0.002)。很少有制药商支持的试验支持传统疗法；这一发现的一些原因可能包括选择可能被证明有效的药物。第二类错误(假阴性研究)，以及担心一旦提交此类研究就停止资助。如果不发表阴性研究，重要的临床信息可能会丢失。
Because of recent concerns about conflicts of interest and published research, the author analyzed 107 controlled clinical trials. Studies were classified as favoring either a new therapy or a traditional therapy, and as being supported by a pharmaceutical manufacturer or as being generally supported. Seventy-one per cent of the trials favored new therapies; 43% of these were funded by pharmaceutical firms. Of the 31 trials favoring traditional therapy, only four (13%) were supported by a pharmaceutical firm. There was a statistically significant association between the source of funding and the outcome of the study (p = 0.002). Few trials supported by pharmaceutical manufacturers favored traditional therapy; some reasons for this finding may include selection of drugs likely to be proven efficacious. Type II errors (false-negative studies), and fear of discontinuation of funding should such studies be submitted. Important clinical information may be lost if negative studies are not published.